Genetic testing company Myriad Genetics (NASDAQ:MYGN) reported Q3 2026 results , but revenue fell by 1.5% year on year to ...

Myriad Genetics (NASDAQ:MYGN) reported third-quarter revenue of $202.7 million, down 1% from a year earlier, as growth in ...

<?xml encoding="utf-8" ?> Myriad Genetics MYGN reported third-quarter financial results on Wednesday. The transcript from the ...

Gallstone disease is common, but its genetic basis remains incompletely understood. Here, the authors conduct a trans‑ancestry GWAS identifying 116 risk loci, linking gallstone susceptibility to lipid ...

Highlights Third quarter 2026 revenue was $202.7 million, representing a 6% sequential increase and a 1% decrease year-over-year. Higher Cancer Care Continuum (CCC) product mix and continued progress ...

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its third quarter 2026 earnings conference call at 4:30 pm ET on Wednesday, November 4 ...

Bergen, Norway-based aquaculture genetics solutions firm Benchmark Genetics announced the release of a new DNA parentage test for shrimp-breeding programs called BenchTrace. The new program will help ...

New MONSTAR-SCREEN-3 Data Support Utility of Ultra-Sensitive MRD Detection Across Colorectal and Pancreatic Cancers ...

Following the news, Myriad Genetics shares are surging 29.10% to $5.45. Labcorp provides laboratory services to doctors, hospitals, and pharmaceutical companies, while Myriad Genetics develops and ...

SALT LAKE CITY, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic ...

Behavioural genetics is the interdisciplinary effort to establish causal links between genes and animal (including human) behavioural traits and neural mechanisms. Methods used include twin studies, ...